Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Cifurtilimab (SEA-CD40), a nonfucosylated humanized IgG1 monoclonal antibody with agonistic properties, targets the CD40 receptor and demonstrates antitumor activities [1] [2].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Cifurtilimab (SEA-CD40), a nonfucosylated humanized IgG1 monoclonal antibody with agonistic properties, targets the CD40 receptor and demonstrates antitumor activities [1] [2]. |
In vitro | Cifurtilimab enhances FcγRIIIa binding (10-fold higher than parental IgG1 antibodies), bolstering effector functions, resulting in a stronger immunostimulatory activity compared to antibodies with silenced or selective FcγR binding [1]. Exposure to Cifurtilimab elicits distinct response features, such as the activation of APCs, CD8+ and CD4+ T cells, NK cells, and targeted depletion of CD40+ B cells [1]. |
In vivo | In preclinical murine models, the combined use of Cifurtilimab with chemotherapy agents enhanced antitumor activity [2]. |
Synonyms | SEA-CD40 |
Molecular Weight | N/A |
CAS No. | 1629760-27-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Cifurtilimab 1629760-27-5 SEA-CD40 inhibitor inhibit